MX2011006555A - Compuestos de tiazolopiridina moduladores de sirtuina. - Google Patents
Compuestos de tiazolopiridina moduladores de sirtuina.Info
- Publication number
- MX2011006555A MX2011006555A MX2011006555A MX2011006555A MX2011006555A MX 2011006555 A MX2011006555 A MX 2011006555A MX 2011006555 A MX2011006555 A MX 2011006555A MX 2011006555 A MX2011006555 A MX 2011006555A MX 2011006555 A MX2011006555 A MX 2011006555A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- sirtuin
- modulating compounds
- disorders
- thiazolopyridine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 102000011990 Sirtuin Human genes 0.000 title 1
- 108050002485 Sirtuin Proteins 0.000 title 1
- WFIHKLWVLPBMIQ-UHFFFAOYSA-N [1,3]thiazolo[5,4-b]pyridine Chemical compound C1=CN=C2SC=NC2=C1 WFIHKLWVLPBMIQ-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010053567 Coagulopathies Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000011010 flushing procedure Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002438 mitochondrial effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000035882 stress Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente se proveen compuestos novedosos moduladores de sirtuina de la fórmula estructural (la) (ver formula (la)) y métodos de uso de los mismos; los compuestos moduladores de sirtuina pueden ser usados para aumentar el tiempo de vida de una célula, y para tratar y/o prevenir una amplia variedad de enfermedades y trastornos que incluyen, por ejemplo, trastornos relacionados con el envejecimiento o estrés, diabetes, obesidad, enfermedades neurodegenerativas, enfermedad cardiovascular, trastornos de la coagulación sanguínea, inflamación, cáncer, y/o enrojecimiento así como enfermedades y trastornos que puedan beneficiarse de una actividad mitocondrial aumentada; también se proveen composiciones que comprenden un compuesto modulador de sirtuina en combinación con otro agente terapéutico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20315608P | 2008-12-19 | 2008-12-19 | |
PCT/US2009/068865 WO2010071853A1 (en) | 2008-12-19 | 2009-12-18 | Thiazolopyridine sirtuin modulating compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011006555A true MX2011006555A (es) | 2011-08-03 |
Family
ID=42269132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011006555A MX2011006555A (es) | 2008-12-19 | 2009-12-18 | Compuestos de tiazolopiridina moduladores de sirtuina. |
Country Status (22)
Country | Link |
---|---|
US (2) | US8343997B2 (es) |
EP (1) | EP2376502B1 (es) |
JP (1) | JP5628828B2 (es) |
KR (1) | KR20110110194A (es) |
CN (1) | CN102388054B (es) |
BR (1) | BRPI0922435A2 (es) |
CA (1) | CA2747715A1 (es) |
CO (1) | CO6400181A2 (es) |
CR (1) | CR20110353A (es) |
DO (1) | DOP2011000188A (es) |
EA (1) | EA021424B1 (es) |
ES (1) | ES2544258T3 (es) |
IL (1) | IL213217A0 (es) |
MA (1) | MA32909B1 (es) |
MX (1) | MX2011006555A (es) |
MY (1) | MY160006A (es) |
NZ (1) | NZ594122A (es) |
PE (1) | PE20120057A1 (es) |
SG (1) | SG171835A1 (es) |
UA (1) | UA104447C2 (es) |
WO (1) | WO2010071853A1 (es) |
ZA (1) | ZA201104060B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
ES2586459T3 (es) | 2008-05-01 | 2016-10-14 | Glaxosmithkline Llc | Quinolinas y análogos relacionados como moduladores de sirtuina |
MX2011000079A (es) * | 2008-07-03 | 2011-03-02 | Sirtris Pharmaceuticals Inc | Bencimidazoles y analogos relacionados como moduladores de sirtuin. |
MX2011003372A (es) | 2008-09-29 | 2011-06-09 | Sirtris Pharmaceuticals Inc | Analogos de cromenona como modulares de sirtuina. |
WO2011059839A1 (en) | 2009-10-29 | 2011-05-19 | Sirtris Pharmaceuticals, Inc. | Bicyclic pyridines and analogs as sirtuin modulators |
US20150087687A1 (en) | 2012-03-23 | 2015-03-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
CN104812393A (zh) | 2012-05-08 | 2015-07-29 | 默沙东公司 | 用于抑制RORγ活性和治疗疾病的四氢萘啶和相关双环化合物 |
AU2013259624B2 (en) | 2012-05-08 | 2017-10-19 | Lycera Corporation | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
WO2013186089A2 (en) | 2012-06-14 | 2013-12-19 | Basf Se | Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests |
WO2016081692A2 (en) * | 2014-11-19 | 2016-05-26 | Glaxosmithkline Llc | Substituted bridged urea analogs as sirtuin modulators |
BR112015028613A2 (pt) | 2013-05-13 | 2017-07-25 | Glaxosmithkline Llc | análogos de uréia com ligações por pontes substituída como moduladores de sirtuína |
US10172915B2 (en) | 2013-10-20 | 2019-01-08 | Duke University | Methods and compositions for activation of sirtuins with Annexin A1 peptides |
US9663502B2 (en) | 2013-12-20 | 2017-05-30 | Lycera Corporation | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease |
WO2015095795A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
WO2015095792A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease |
US10532088B2 (en) | 2014-02-27 | 2020-01-14 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods |
EP3209641A4 (en) | 2014-05-05 | 2018-06-06 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease |
US9896441B2 (en) | 2014-05-05 | 2018-02-20 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
MX2016015997A (es) | 2014-06-02 | 2017-04-05 | Glaxosmithkline Intellectual Property (No 2) Ltd | Preparacion y uso de beta-d-nicotinamida ribosido cristalina. |
EP3152220A1 (en) | 2014-06-06 | 2017-04-12 | Glaxosmithkline Intellectual Property (No. 2) Limited | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof |
WO2016130818A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
AU2016257997A1 (en) | 2015-05-05 | 2017-11-09 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
JP6838004B2 (ja) | 2015-06-11 | 2021-03-03 | リセラ・コーポレイションLycera Corporation | RORγのアゴニストとしての使用及び疾患の治療のためのアリールジヒドロ−2H−ベンゾ[b][1,4]オキサジンスルホンアミド及び関連化合物 |
WO2017075182A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as rorgammat inhibitors and uses thereof |
US10344000B2 (en) | 2015-10-27 | 2019-07-09 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
JP2018531958A (ja) | 2015-10-27 | 2018-11-01 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | RORγT阻害薬としてのヘテロアリール置換安息香酸及びその使用 |
AU2017223706A1 (en) | 2016-02-23 | 2018-09-20 | Indiana University Research & Technology Corporation | Combination therapies for treatment of spinal muscular atrophy |
WO2020247608A1 (en) * | 2019-06-04 | 2020-12-10 | The Regents Of The University Of California | Small molecule inhibitors of a protein complex |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3164603A (en) | 1965-01-05 | xnhcox | ||
DE1108698B (de) | 1959-09-03 | 1961-06-15 | Hoechst Ag | Verfahren zur Herstellung von 2-(2'-Aminoaryl)-4, 5-arylen-1, 2, 3-triazolen |
FR1439129A (fr) | 1965-04-02 | 1966-05-20 | Chimetron | Nouveaux sulfonylbenzimidazoles |
FR1476529A (fr) | 1965-04-24 | 1967-04-14 | Chimetron Sarl | Nouveaux dérivés benzimidazole-sulfoniques et sulfamides correspondants |
US3503929A (en) | 1965-10-21 | 1970-03-31 | Minnesota Mining & Mfg | Polyimidazoquinazolines and polyamidobenzimidazoles |
US3517007A (en) | 1968-04-05 | 1970-06-23 | American Home Prod | 5 - acetamido - 4 - pyrimidinecarboxamides,5 - acetamido - 4 - pyrimidinecarboxylic acid hydrazides and related compounds |
US3928228A (en) | 1969-04-28 | 1975-12-23 | Sterling Drug Inc | 4,4{40 -Stilbenebis-pyridooxazoles and related optical brighteners and polymeric compositions brightened thereby |
US3712888A (en) | 1970-12-14 | 1973-01-23 | American Cyanamid Co | Bis-pyridoxazole-stilbene derivatives for optical brightening |
CA1006165A (en) | 1971-04-06 | 1977-03-01 | Eastman Kodak Company | Ballasted color photographic couplers |
AR208500A1 (es) | 1972-06-14 | 1977-02-15 | Merck & Co Inc | Procedimiento para la preparacion de derivados de oxazolo(4,5-b)-piridinas |
US4038396A (en) | 1975-02-24 | 1977-07-26 | Merck & Co., Inc. | Anti-inflammatory oxazole[4,5-b]pyridines |
PL96241B1 (pl) | 1975-06-30 | 1977-12-31 | Sposob wytwarzania 2-/2-podstawionych-4-tiazolilo/-benzimidazoli | |
JPS6040016B2 (ja) | 1977-08-31 | 1985-09-09 | コニカ株式会社 | マゼンタ色素画像の形成方法 |
US4471040A (en) | 1980-09-10 | 1984-09-11 | Canon Kabushiki Kaisha | Electrophotographic disazo photosensitive member |
US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4939133A (en) | 1985-10-01 | 1990-07-03 | Warner-Lambert Company | N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade |
DE3807084A1 (de) | 1988-03-04 | 1989-09-14 | Knoll Ag | Neue benzimidazo(1,2-c)chinazoline, ihre herstellung und verwendung |
JPH04190232A (ja) | 1990-11-26 | 1992-07-08 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
US5814651A (en) | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
JPH06247969A (ja) | 1992-12-28 | 1994-09-06 | Takeda Chem Ind Ltd | 縮合複素環化合物及びそれを含む農園芸用殺虫剤 |
EP0711768B1 (en) | 1994-05-31 | 2002-02-13 | Mitsui Chemicals, Inc. | Benzimidazole derivative |
AUPN449295A0 (en) | 1995-07-28 | 1995-08-24 | Inner And Eastern Health Care Network, The | Radioprotectors |
WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
US5808087A (en) | 1995-11-29 | 1998-09-15 | Mitsui Chemicals, Inc. | Sulfonium salts of pyrrolylbenzimidazoles |
WO1999033824A1 (en) | 1997-12-31 | 1999-07-08 | Rutgers, The State University Of New Jersey | Heterocyclic topoisomerase poisons |
US6653309B1 (en) | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
DE60023128T2 (de) | 1999-05-12 | 2006-07-06 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazolcarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen |
SI1194425T1 (sl) | 1999-06-23 | 2005-12-31 | Sanofi Aventis Deutschland | Substituirani benzimidazoli |
AU7314200A (en) | 1999-09-17 | 2001-04-24 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
AU2001259707A1 (en) | 2000-06-14 | 2001-12-24 | Warner Lambert Company | 6,5-fused bicyclic heterocycles |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
JP2002161084A (ja) | 2000-11-28 | 2002-06-04 | Sumitomo Pharmaceut Co Ltd | 複素環誘導体 |
US20040010033A1 (en) | 2001-02-20 | 2004-01-15 | Pfizer Inc. | Non-peptide GnRH agents, methods and intermediates for their preparation |
WO2002066454A1 (en) | 2001-02-21 | 2002-08-29 | Sankyo Company, Limited | Chromene derivatives |
CA2442428A1 (en) | 2001-03-28 | 2002-10-10 | Mark D. Wittman | Novel tyrosine kinase inhibitors |
US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
PL366799A1 (en) | 2001-07-27 | 2005-02-07 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
WO2004043335A2 (en) | 2001-09-13 | 2004-05-27 | Genesoft, Inc. | Methods of treating infection by drug resistant bacteria |
US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
WO2003045929A1 (fr) | 2001-11-26 | 2003-06-05 | Takeda Chemical Industries, Ltd. | Derive bicyclique, procede de production de ce derive et utilisation correspondante |
AU2002349705A1 (en) | 2001-12-03 | 2003-06-17 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
RU2004126671A (ru) | 2002-02-06 | 2005-04-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Гетероарилсоединения, полезные в качестве ингибиторов gsk-3 |
GB0205256D0 (en) | 2002-03-06 | 2002-04-17 | Oxford Glycosciences Uk Ltd | Novel compounds |
AU2003209896A1 (en) | 2002-03-18 | 2003-09-29 | Merck Frosst Canada And Co. | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors |
WO2003080545A2 (en) | 2002-03-20 | 2003-10-02 | Metabolex, Inc. | Substituted phenylacetic acids |
TW200304820A (en) | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
JP4239463B2 (ja) | 2002-04-09 | 2009-03-18 | 大正製薬株式会社 | 3−トリフルオロメチルアニリド誘導体 |
JP4224979B2 (ja) | 2002-04-09 | 2009-02-18 | 大正製薬株式会社 | インターロイキン12抑制剤 |
JP4563800B2 (ja) | 2002-04-18 | 2010-10-13 | シェーリング コーポレイション | ヒスタミンh3アンタゴニストとしての1−(4−ピペリジニル)ベンズイミダゾロン |
JP2003313176A (ja) | 2002-04-24 | 2003-11-06 | Sankyo Co Ltd | アミノアゾール誘導体 |
AU2003249937A1 (en) | 2002-07-12 | 2004-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclically substituted benzoylureas, method for their production and their use as medicaments |
SE0202429D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel Compounds |
DE10237722A1 (de) | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
JP2004075614A (ja) | 2002-08-20 | 2004-03-11 | Sankyo Co Ltd | クロメン誘導体を含有する医薬 |
TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
US20040171073A1 (en) | 2002-10-08 | 2004-09-02 | Massachusetts Institute Of Technology | Compounds for modulation of cholesterol transport |
AU2003263518A1 (en) | 2002-10-09 | 2004-05-04 | Pfizer Products Inc. | Pyrazole compounds for treatment of neurodegenerative disorders |
US8252520B2 (en) | 2002-10-11 | 2012-08-28 | Taivex Therapeutics Corporation | Methods and compounds for inhibiting Hec1 activity for the treatment of proliferative diseases |
US7265129B2 (en) | 2002-10-25 | 2007-09-04 | Genesoft Pharmaceuticals, Inc. | Anti-infective biaryl compounds |
JP2006513159A (ja) | 2002-11-01 | 2006-04-20 | メルク エンド カムパニー インコーポレーテッド | アンドロゲン受容体モジュレーターとしてのカルボニルアミノ−ベンズイミダゾール誘導体 |
WO2004050833A2 (en) | 2002-11-27 | 2004-06-17 | University Of North Carolina At Chapel Hill | Glyceraldehyde 3-phosphate dehydrogenase-s(gapds), a glycolytic enzyme expressed only in male germ cells,is a target for male contraception |
DE10300398A1 (de) | 2003-01-09 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von substituierten 2-Phenylbenzimidazolen als Arzneimittel |
WO2004069160A2 (en) | 2003-01-28 | 2004-08-19 | Smithkline Beecham Corporation | Chemical compounds |
JP2006517234A (ja) | 2003-02-10 | 2006-07-20 | アムジエン・インコーポレーテツド | バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用 |
US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
CN103265477B (zh) | 2003-02-26 | 2017-01-11 | 苏根公司 | 作为蛋白激酶抑制剂的氨基杂芳基化合物 |
JP2006519833A (ja) | 2003-03-11 | 2006-08-31 | ファイザー・プロダクツ・インク | トランスフォーミング成長因子(tgf)阻害剤としてのピラジン化合物 |
JP2006520794A (ja) | 2003-03-21 | 2006-09-14 | スミスクライン ビーチャム コーポレーション | 化合物 |
TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
WO2005025574A2 (en) | 2003-09-12 | 2005-03-24 | 4 Aza Bioscience Nv | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. |
GB2405793A (en) | 2003-09-12 | 2005-03-16 | 4 Aza Bioscience Nv | Pteridine derivatives for treating TNF-alpha related disorders |
RU2006112847A (ru) | 2003-09-19 | 2007-11-10 | Ф. Хоффманн-Ля Рош Аг (Ch) | Производные тиазолопиридина в качестве лигандов аденозинового рецептора |
JP4795634B2 (ja) | 2003-10-31 | 2011-10-19 | 出光興産株式会社 | 有機薄膜トランジスタ |
JP2005162855A (ja) | 2003-12-02 | 2005-06-23 | Konica Minolta Holdings Inc | 着色組成物、インクジェット記録用インク、カラートナー、光記録媒体、感熱転写記録材料用インクシート、カラーフィルター、及び該インクジェット記録用インクを用いたインクジェット記録方法 |
DK1723138T3 (da) | 2004-02-11 | 2010-08-23 | Basilea Pharmaceutica Ag | Substituerede benzimidazoler og deres anvendelse til at inducere apoptose |
WO2005100342A1 (en) | 2004-03-26 | 2005-10-27 | Vertex Pharmaceuticals, Incorporated | Pyridine inhibitors of erk2 and uses thereof |
DE102004021716A1 (de) | 2004-04-30 | 2005-12-01 | Grünenthal GmbH | Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen |
TW200600492A (en) | 2004-05-18 | 2006-01-01 | Achillion Pharmaceuticals Inc | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
EP2489659B1 (en) | 2004-06-24 | 2017-12-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
AR050917A1 (es) | 2004-08-13 | 2006-12-06 | Amphora Discovery Corp | Compuestos basados en 2-amido-tiazol que presentan actividad inhibidora de enzimas que utilizan atp, y composiciones y usos de los mismos |
DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
EP1807074B1 (en) | 2004-11-03 | 2013-10-23 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
WO2006053227A2 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
WO2006094236A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N-phenyl benzamide derivatives as sirtuin modulators |
US20090069301A1 (en) | 2005-03-03 | 2009-03-12 | Sirtris Pharmaceuticals, Inc. | Acridine and Quinoline Derivatives as Sirtuin Modulators |
US20060235037A1 (en) | 2005-04-15 | 2006-10-19 | Purandare Ashok V | Heterocyclic inhibitors of protein arginine methyl transferases |
US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
WO2007019346A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Benzothiazoles and thiazolopyridines as sirtuin modulators |
CN101277965A (zh) * | 2005-08-04 | 2008-10-01 | 西特里斯药业公司 | 作为SIRTUIN调节化合物的咪唑并[2,1-b]噻唑衍生物 |
KR101354265B1 (ko) | 2006-07-14 | 2014-01-22 | 토요잉크Sc홀딩스주식회사 | 폴리에스테르 분산제와 그의 제조방법, 및 그것을 이용한 안료 조성물 |
WO2008073451A2 (en) | 2006-12-11 | 2008-06-19 | Sirtris Pharmaceuticals, Inc. | Benzoimidazole derivatives as sirtuin (sir) modulating compounds |
US8822497B2 (en) | 2007-03-01 | 2014-09-02 | Novartis Ag | PIM kinase inhibitors and methods of their use |
CL2008001822A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
CL2008001821A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
AU2008319267A1 (en) | 2007-11-01 | 2009-05-07 | Sirtris Pharmaceuticals, Inc. | Amide derivatives as sirtuin modulators |
CN101910184A (zh) | 2007-11-08 | 2010-12-08 | 西特里斯药业公司 | 可溶性噻唑并吡啶 |
US20100168084A1 (en) | 2008-05-08 | 2010-07-01 | Huber L Julie | Therapeutic compounds and related methods of use |
WO2010019606A1 (en) | 2008-08-12 | 2010-02-18 | Sirtris Pharmaceuticals, Inc. | Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators |
-
2009
- 2009-12-18 ES ES09833859.3T patent/ES2544258T3/es active Active
- 2009-12-18 CN CN200980157247.1A patent/CN102388054B/zh not_active Expired - Fee Related
- 2009-12-18 EP EP09833859.3A patent/EP2376502B1/en active Active
- 2009-12-18 CA CA2747715A patent/CA2747715A1/en not_active Abandoned
- 2009-12-18 NZ NZ594122A patent/NZ594122A/xx not_active IP Right Cessation
- 2009-12-18 WO PCT/US2009/068865 patent/WO2010071853A1/en active Application Filing
- 2009-12-18 PE PE2011001241A patent/PE20120057A1/es not_active Application Discontinuation
- 2009-12-18 UA UAA201109066A patent/UA104447C2/uk unknown
- 2009-12-18 SG SG2011038486A patent/SG171835A1/en unknown
- 2009-12-18 BR BRPI0922435A patent/BRPI0922435A2/pt not_active Application Discontinuation
- 2009-12-18 US US13/139,796 patent/US8343997B2/en not_active Expired - Fee Related
- 2009-12-18 MY MYPI2011002853A patent/MY160006A/en unknown
- 2009-12-18 EA EA201170847A patent/EA021424B1/ru not_active IP Right Cessation
- 2009-12-18 MX MX2011006555A patent/MX2011006555A/es active IP Right Grant
- 2009-12-18 KR KR1020117016678A patent/KR20110110194A/ko active IP Right Grant
- 2009-12-18 JP JP2011542514A patent/JP5628828B2/ja not_active Expired - Fee Related
-
2011
- 2011-05-30 IL IL213217A patent/IL213217A0/en unknown
- 2011-06-01 ZA ZA2011/04060A patent/ZA201104060B/en unknown
- 2011-06-15 DO DO2011000188A patent/DOP2011000188A/es unknown
- 2011-06-17 MA MA33955A patent/MA32909B1/fr unknown
- 2011-06-22 CR CR20110353A patent/CR20110353A/es unknown
- 2011-06-23 CO CO11079280A patent/CO6400181A2/es active IP Right Grant
-
2012
- 2012-11-15 US US13/678,292 patent/US8492401B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CO6400181A2 (es) | 2012-03-15 |
US20130085155A1 (en) | 2013-04-04 |
EP2376502B1 (en) | 2015-06-17 |
IL213217A0 (en) | 2011-07-31 |
EP2376502A1 (en) | 2011-10-19 |
BRPI0922435A2 (pt) | 2018-09-11 |
AU2009327373A1 (en) | 2011-06-30 |
JP5628828B2 (ja) | 2014-11-19 |
JP2012512907A (ja) | 2012-06-07 |
CA2747715A1 (en) | 2010-06-24 |
US8343997B2 (en) | 2013-01-01 |
SG171835A1 (en) | 2011-07-28 |
EA021424B1 (ru) | 2015-06-30 |
ZA201104060B (en) | 2012-02-29 |
EP2376502A4 (en) | 2012-07-18 |
CN102388054B (zh) | 2015-03-04 |
US20110306609A1 (en) | 2011-12-15 |
EA201170847A1 (ru) | 2011-12-30 |
US8492401B2 (en) | 2013-07-23 |
MA32909B1 (fr) | 2011-12-01 |
UA104447C2 (uk) | 2014-02-10 |
PE20120057A1 (es) | 2012-02-24 |
CN102388054A (zh) | 2012-03-21 |
ES2544258T3 (es) | 2015-08-28 |
KR20110110194A (ko) | 2011-10-06 |
NZ594122A (en) | 2013-03-28 |
WO2010071853A1 (en) | 2010-06-24 |
DOP2011000188A (es) | 2011-07-31 |
MY160006A (en) | 2017-02-15 |
CR20110353A (es) | 2011-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA104447C2 (uk) | Тіазолопіридинові сполуки, що модулюють сиртуїн | |
MY149316A (en) | Sirtuin modulating imidazohiazole compounds | |
MX2009013977A (es) | Compuestos de tiazolopiridina moduladores de sirtuinas. | |
MX2010012961A (es) | Imidazopiridina y analogos relacionados como moduladores de sirtuina. | |
IN2012DN03799A (es) | ||
WO2009134973A8 (en) | Quinolines and related analogs as sirtuin modulators | |
EP2344475A4 (en) | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGUES AS MODULATORS OF SIRTUINE | |
MX2011006475A (es) | Ftalazinona y analogos relacionados como moduladores de sirtuina. | |
MX2011006084A (es) | Isoindolinona y analogos relacionados como moduladores de sirtuina. | |
MX2010004965A (es) | Derivados de amida como moduladores de la sirtuina. | |
MX2011009213A (es) | Quinolinas 8-sustituidas y analogos relacionados como moduladores de sirtuina. | |
WO2006094209A3 (en) | N-benzimidazolylalkyl-substituted amide sirtuin modulators | |
MX2010005186A (es) | Tiazolopiridinas solubilizadas. | |
WO2006094210A3 (en) | Tetrahydroquinoxalinone sirtuin modulators | |
AU2014265671A8 (en) | Substituted bridged urea analogs as sirtuin modulators | |
EA201170137A1 (ru) | Бензимидазолы и родственные аналоги в качестве модуляторов сиртуина | |
WO2006094246A3 (en) | N-arylmethyl benzamide sirtuin modulators | |
WO2007019344A8 (en) | Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds | |
WO2006105440A3 (en) | Nicotinamide riboside and analogues thereof | |
WO2006078941A3 (en) | Novel sirtuin activating compounds and methods of use thereof | |
WO2008100376A3 (en) | Truncation variants of sirt1 and methods of use thereof | |
CR9347A (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
WO2009085226A3 (en) | Inhibitors of cdc2-like kinases (clks) and methods of use thereof | |
WO2016081692A3 (en) | Substituted bridged urea analogs as sirtuin modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |